All In Biotech

NDA 018680 · Coopersurgical

Paragard T 380a

Copper · Intrauterine · Copper-containing Intrauterine Device

Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1984

Nov 15, 1984

Approved uses

6

Original approval plus efficacy supplements

Registered trials

158

26 Phase 3, 16 recruiting

FAERS reports

43,152

19,749 serious, 60 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 19, 2026.

Paragard is indicated for prevention of pregnancy in females of reproductive potential for up to 10 years. Paragard is a copper-containing intrauterine system (IUS) indicated for prevention of pregnancy in females of reproductive potential for up to 10 years. ( 1 )

Mechanism: Copper continuously released into the uterine cavity contributes to the contraceptive effectiveness of Paragard. Mechanism(s) by which copper enhances contraceptive efficacy include interference with sperm transport and fertilization of an egg, and possibly prevention of implantation.

Therapeutic areas: Endocrinology and women's health

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 28, 2024 Supplement 74 · Efficacy LabelLetterReview
  • Sep 1, 2005 Supplement 60 · Efficacy LabelLetter
  • May 19, 1994 Supplement 26 · Efficacy
  • Aug 13, 1991 Supplement 16 · Efficacy
  • Jul 17, 1989 Supplement 8 · Efficacy
  • Nov 15, 1984 Original approval · Type 3 - New Dosage Form Review
1 products under this application
  • PARAGARD T 380A · COPPER 309MG/COPPER · SYSTEM, INTRAUTERINE · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Copper" as an intervention, any sponsor and status, largest first.

All 158 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • device breakage11,399
  • device expulsion11,259
  • complication of device removal10,261
  • foreign body in reproductive tract8,905
  • complication of device insertion8,360
  • device dislocation7,298
  • pain6,048
  • embedded device4,782
  • reproductive complication associated with device3,566
  • emotional distress3,129
  • anxiety3,117
  • off label use2,864

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041
20054
20063
200711
2008110
200958
2010139
2011187
201265
201340
2014243
20153,156
20163,078
20173,430
20181,080
20197,055
20203,507
20213,298
20222,204
20234,300
20243,086
20253,247
20264,850

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,074 on PubMed

Sponsor: Coopersurgical

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.